As of Oct 18
| +0.12 / +0.62%|
The 8 analysts offering 12-month price forecasts for Iovance Biotherapeutics Inc have a median target of 32.00, with a high estimate of 56.00 and a low estimate of 27.00. The median estimate represents a +63.52% increase from the last price of 19.57.
The current consensus among 9 polled investment analysts is to Buy stock in Iovance Biotherapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.